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Introduction {#s1}
============

Pulmonary hypertension (PH) is a severe condition characterized by elevated mean pulmonary arterial pressure ≥25 mmHg resulting in right heart failure and death [@pone.0115219-Rubin1]. According to recent guidelines, PH can be classified based on clinical and haemodynamic criteria. One distinct subgroup of pulmonary arterial hypertension (PAH) is pulmonary veno-occlusive disease (PVOD) [@pone.0115219-Simonneau1], [@pone.0115219-Galie1], which accounts for only 5--10% of all cases of PAH [@pone.0115219-Mandel1]. In contrast to the involvement of small pre-capillary pulmonary arteries as in PAH, vascular pathology in PVOD is characterized by fibrous remodeling of post-capillary septal veins and praeseptal venules [@pone.0115219-Huertas1], [@pone.0115219-Pietra1].

Clinical presentation of PVOD is non-specific and very similar to PAH. Hence, distinguishing PVOD from PAH based on clinical criteria is often difficult. Nevertheless, since PVOD has a worse prognosis than the various forms of PAH and may exhibit a poor and even adverse response to common vasodilator therapies which may lead to severe and sometimes fatal pulmonary oedema, it is of crucial importance to identify cases of PVOD. In addition, a diagnosis of PVOD has serious therapeutic consequences since such patient qualify for lung transplantation and should be listed as soon as possible.

PVOD can be suspected by the constellation of significant hypoxaemia, a very low carbon monoxide diffusion capacity (DLCO) as well as characteristic radiological features on chest computed tomography [@pone.0115219-Palmer1]--[@pone.0115219-Holcomb1]. The definitive diagnosis of PVOD would require surgical lung biopsy, but such an invasive approach is not feasible in these high-risk patients. Hence, less invasive diagnostic tools would be helpful. As mentioned, PVOD affects the post-capillary veins and may hence result in engorgement of the capillaries leading to occult alveolar haemorrhage. Indeed, a study of bronchoalveolar lavage (BAL) in patients suffering from PVOD could demonstrate a significantly higher percentage of haemosiderin-laden macrophages as compared to other form of PH [@pone.0115219-Rabiller1]. Hence, BAL has become an additional investigation tool to diagnose PVOD. Nevertheless, even though BAL has been reported to be a safe intervention in stable PH patients [@pone.0115219-Rabiller1], it is an invasive procedure and may carry an increased risk of respiratory impairment and hemodynamic instability. Thus, there is an urgent need for a less invasive procedure. The aim of the current study is to investigate whether the analysis of haemosiderin-laden macrophages in the sputum of patients, might represent an additional diagnostic tool in the work-up for PVOD comparable to BAL.

Materials and Methods {#s2}
=====================

Patient data {#s2a}
------------

The study was conducted at the Pulmonary Hypertension Unit, University Hospital Zurich, Switzerland, between July 2003 and November 2011. PVOD was assumed with a mean pulmonary arterial pressure of ≥25 mmHg, a pulmonary arterial wedge pressure ≤15 mmHg and the presence of at least 2 out of 3 chest computed tomography findings (centrilobular ground-glass opacities, septal lines and mediastinal lymph node enlargement) [@pone.0115219-Resten1], as well as laboratory findings suggestive for PVOD, i.e. a reduced diffusion capacity of the lungs for carbon monoxide (DLCO; \<50%) and hypoxaemia at rest with a PaO~2~\<8 kPa, and clinical sings like crackles on auscultation or pulmonary oedema after vasodilator therapy [@pone.0115219-Montani1], [@pone.0115219-Holcomb1], [@pone.0115219-Elliott1]. Pathological confirmation of PVOD could be obtained in only one patient from the explanted lungs after lung transplantation.

As control groups, patients suffering from idiopathic PAH (IPAH; n = 11) [@pone.0115219-Zamanian1], [@pone.0115219-Simonneau2], chronic thromboembolic PH (CTEPH; n = 9) [@pone.0115219-Zamanian1]--[@pone.0115219-Lang1], and scleroderma-associated PAH (SPAH; n = 10) [@pone.0115219-Zamanian1], [@pone.0115219-Simonneau2], [@pone.0115219-Chaisson1] were included in this analysis. The diagnosis of these entities was established according to current guidelines [@pone.0115219-Zamanian1]--[@pone.0115219-Chaisson1].

Ethical approval was granted by the institutional ethical committee ("Kantonale Ethikkommission Zürich"). All subjects signed an informed consent form.

Sputum collection and processing {#s2b}
--------------------------------

Sputum from every patient was obtained by a non-invasive manner without any induction by hypertonic saline solution. Per visit, each patient has given three probes of sputum which where stained for haemosiderin by the Prussian blue procedure. The patients were encouraged as far as possible to produce a viable sputum sample. However, after 5 attempts the procedure was halted in consideration of the reduced general condition of these patients. The slides were stored and then examined by two physicians unaware of the clinical course of the patients (H.L., B.M.). Quality criteria for sputum was presence of more than 25 macrophages on the slides. The haemosiderin content of alveolar macrophages was estimated according to the Golde scoring system [@pone.0115219-Golde1]. Each macrophage was scored for haemosiderin content using the following scale: 0, no color; 1, faint blue in a part or the whole cytoplasm without or with single deep blue granules; 2, medium color intensity throughout the cytoplasm without or with deep blue granules in minor (\<50%) portions of the cytoplasm; 3, deep blue granules in major (\>50%) portions of the cytoplasm; and 4, deep blue granules throughout the cell ([Fig. 1](#pone-0115219-g001){ref-type="fig"}). The total score was extrapolated to an average of 100 cells.

![Description of the Golde score calculation in sputum macrophages.](pone.0115219.g001){#pone-0115219-g001}

Statistical analysis {#s2c}
--------------------

Continuous variables are expressed as median (interquartile range) and frequencies for categorical variables. The Golde score was analyzed by the Kruskal-Wallis One-Way analysis of variance, the Spearman\'s coefficient of correlation was used to assess inter-observer variation in the analysis of the Golde score. Clinical data was analyzed by the χ^2^ test for categorical and by the Kruskal-Wallis One-Way analysis for continuous data. The level of significance was defined as a two-tailed *P* value \<0.05. All statistical analyses were performed with SPSS Statistics 19.0 for Windows (SPSS, Inc. 2010).

Results {#s3}
=======

Patient\'s characteristics {#s3a}
--------------------------

36 subjects were included in the present study: IPAH (n = 11), CTEPH (n = 9), SAPH (n = 10), and PVOD (n = 6). A detailed overview of the patient\'s characteristics is summarized in [table 1](#pone-0115219-t001){ref-type="table"}. Briefly, there was a non-significant trend towards higher age in the PVODs (70±6 years in PVOD versus 55±20 years for IPAH, 63±16 years for CTEPH, and 67±10 years for SAPH, respectively; *P* = NS), while there was a female predominance in the SAPH group as compared to the others (100% female in SAPH versus 36.4% for IPAH, 44.4% for CTEPH, and 20.0% for PVOD; *P*\<0.05). Dyspnea was the main symptom in all patients with the majority suffering from New York Heart association functional class III-IV. The 6-minute walking distance (6-MWD) as well as the mean pulmonary artery pressure and the cardiac index did not differ significantly between the groups.

10.1371/journal.pone.0115219.t001

###### Clinical characteristics of the four patient groups.

![](pone.0115219.t001){#pone-0115219-t001-1}

                                                    Group                          
  ---------------------------------------------- ----------- ---------- ---------- -----------
  **Gender \[m/f\]**                                 7/4        5/4        0/10        5/1
  **Age \[years\]**                                 55±20      63±16      67±10       70±6
  **Smoking \[%\]**                                  36          13         10         33
  **NYHA functional class \[n\]**                                                  
  **I-II**                                          2/11        4/9        2/10        1/6
  **III-IV**                                        9/11        5/9        8/10        5/6
  **Baseline 6-MWD \[m\]**                         292±127    431±183    359±160     295±74
  **Heart rate \[bpm\]**                            77±10      92±17      78±16       82±13
  **Systolic blood pressure \[mmHg\]**             117±17      134±24     118±15     119±20
  **Diastolic blood pressure \[mmHg\]**             68±8       74±14      68±12       71±11
  **Mean pulmonary artery pressure \[mmHg\]**       44±16      45±17      32±12       39±11
  **Pulmonary artery wedge pressure \[mmHg\]**      13±10       11±7       13±5        8±3
  **Central venous pressure \[mmHg\]**               9±5        8±6        7±5         6±4
  **Cardiac index \[l/min/m^2^\]**                 3.6±1.3    2.6±0.5    3.1±1.1     2.8±0.5
  **Mixed venous oxygen saturation \[%\]**        65.2±9.1    62.7±9.7   73.0±6.7   60.4±14.2
  **Pulmonary vascular resistance \[WU\]**         6.2±3.1    9.6±5.6    4.6±2.9     6.8±3.5
  **Systemic vascular resistance \[WU\]**         16.0±3--6   21.7±5.9   19.2±6.0   15.2±1.7

In [table 2](#pone-0115219-t002){ref-type="table"}, the clinical features of the 6 patients with suspected PVOD are shown. All of them demonstrated at least 4 findings characteristically associated with PVOD from data of the literature, including at least 2 of the radiologic criteria.

10.1371/journal.pone.0115219.t002

###### Clinical features suggesting the presence of PVOD, number of evaluable cells, and Golde score.

![](pone.0115219.t002){#pone-0115219-t002-2}

  Patient \#    Sex   Age \[years\]   NYHA functional class   6-MWD \[m\]   mPAP \[mmHg\]   CI \[l/min/m^2^\]   PVR \[WU\]   PAWP \[mmHg\]   DLCO \[%\]   PaO~2~ \[kPa\]   Lymphadenopathy   Ground-glass opacity   Septal lines   Crackles or pulmonary oedema   Number of PVOD features   Number of sputum cells   Golde score
  ------------ ----- --------------- ----------------------- ------------- --------------- ------------------- ------------ --------------- ------------ ---------------- ----------------- ---------------------- -------------- ------------------------------ ------------------------- ------------------------ -------------
  1              M         74                  III                296            32                2.9             4.3            11             47            6.78              \+                   \+                 \+                     \-                           5                        48                 264
  2              M         74                  III                372            31                3.0             3.8             9             23            5.32              \+                   \-                 \+                     \+                           5                       143                 270
  3              F         65                  II                 158            38                2.7             7.6             4             47            6.62              \+                   \+                 \-                     \-                           4                       169                 263
  4              M         74                  III                338            32                2.4             5.0             9             39            6.25              \+                   \-                 \+                     \-                           4                       315                 240
  5              M         60                  III                322            38                3.6             6.8             5             33            6.83              \+                   \-                 \+                     \-                           4                       250                 315
  6              M         71                  III                282            60                2.2             13.3           10             48            7.74              \+                   \+                 \+                     \+                           6                       212                 252

6-MWD: 6-minute walking distance. mPAP: mean pulmonary artery pressure. CI: cardiac index. PVR: pulmonary vascular resistance. WU: Wood units. PAWP: pulmonary artery wedge pressure. DLCO: diffusion capacity. PaO~2~: partial pressure of oxygen in arterial blood.

Amount of haemosiderin-laden macrophages is higher in PVOD as compared to the other forms of precapillary PH {#s3b}
------------------------------------------------------------------------------------------------------------

All slides were examined for haemosiderin-laden macrophages by two blinded physicians unaware of the clinical data. The method to calculate the Golde score is summarized in [Fig. 1](#pone-0115219-g001){ref-type="fig"}. The mean of the evaluable sputum macrophages was 267 (median 263; range 240--315). An interobserver variation between the two investigators with respect to the number of identifiable sputum cells as well as to the Golde score could be excluded according to the Spearman\'s coefficient of correlation (r\>0.9). There was no difference in the content of haemosiderin-laden macrophages between IPAH, CTEPH and SPAH (*P* = NS; [Fig. 2](#pone-0115219-g002){ref-type="fig"}). However, there were statistically significant more haemosiderin-laden macrophages in the sputum of patients suffering from PVOD demonstrated by a Golde score\>200 as compared to the other groups (*P*\<0.05; [Fig. 2](#pone-0115219-g002){ref-type="fig"}). All PVOD patients with evaluable cells in their sputum had a Golde score \>200. Assuming a cut-off value for the Golde score of 200, the sensitivity for the diagnosis of clinical PVOD was 100% and the specificity 97%, respectively.

![Haemosiderin-laden macrophages are significantly (*P*\<0.05) more present in sputum from PVOD patients as compared to the others (IPAH, CTEPH and SAPH, respectively).](pone.0115219.g002){#pone-0115219-g002}

For comparison with BAL, we could retrieve only one sample from patient 1 (which was obtained one year before the sputum). The Golde score at that time point was 312, i.e. comparable to the count of 264 found in the sputum. Since all patients except one did not qualify for lung transplantation, we could only assess one histological specimen. Interestingly, this patient also showed features of capillary hemangiomatosis ([Fig. 3](#pone-0115219-g003){ref-type="fig"}). The Golde score calculated from the tissue was 304 and hence comparable to the count of 252 found in the sputum.

![Histologic specimen from a patient suffering from PVOD who underwent lung transplantation.\
Intimal thickening and fibrous obstruction of septal veins and preseptal venules (asterixis) as well as features of pulmonary capillary hemangiomatosis with proliferation of dilated and congested capillaries as well as dilated lymphatic (left upper and right lower part of the figure; arrowhead). Alveoli with haemosiderin-laden macrophages of Golde score 3--4 (arrow) are clearly visible. Haemosiderin-negativ macrophages are difficult to be identified. Golde score from the tissue was 304, as compared to 252 in the sputum.](pone.0115219.g003){#pone-0115219-g003}

Discussion {#s4}
==========

The present analysis demonstrates for the first time that the content of haemosiderin-laden macrophages in the sputum is significantly higher in patients suffering from PVOD as compared to other forms of PH. The sensitivity and specificity for the diagnosis of clinical PVOD was 100% and 97%, respectively. Hence, sputum examination for haemosiderin-laden macrophages may be considered as an additional non-invasive diagnostic piece of puzzle in the work-up of this serious disease. In addition, our study confirms the previous finding of Rabiller and colleagues, who could demonstrate comparable findings by examining alveolar macrophages from BAL [@pone.0115219-Rabiller1].

PVOD is a rare cause of PAH accounting for less than 5--10% of all PAH cases [@pone.0115219-Humbert1]. According to the recent guidelines, PVOD is considered as a subgroup of PAH [@pone.0115219-Galie1]. On one side, the clinical presentation resembles that of PAH including the presence of similar risk factors such as HIV infection. In contrast, the main pathophysiological difference is the fibrous remodeling of post-capillary septal veins and praeseptal venules which is not present in other forms of PAH except to some extent in SPAH [@pone.0115219-Lantuejoul1], [@pone.0115219-Montani2]. Importantly, the involvement of post-capillary vessels allows a histological differentiation between the different entities of PH and also has important implications regarding the therapeutic options. Particularly the use of intravenous as well as oral vasodilators, which are commonly used in the treatment of PAH, may be dangerous due to the risk for development of pulmonary oedema in these patients suffering from PVOD [@pone.0115219-Montani1], [@pone.0115219-Montani2]--[@pone.0115219-Shackelford1]. Therefore, to establish the correct diagnosis is crucial to offer optimal treatment for these patients.

Since lung biopsy is usually not possible in PVOD subjects because it is considered a high-risk procedure in severe PH, one has to rely on clinical features and non-invasive examinations outlined in the algorithm for PVOD management of the French Reference Center for Pulmonary Hypertension[@pone.0115219-Montani1]. In this respect, sputum analysis for haemosiderin-laden macrophages might represent an asset in the diagnostic puzzle. Using a crude Bayesian approach without consideration of dependency of the variables, the likelihood ratios (LHR) of the single parameters can be calculated. For instance, according to the data of Montani and colleagues, the presence of septal lines in a chest computed tomography has a positive (LHR+) and a negative LHR (LHR-) of 4.3 and 0.41, respectively. Due to our data, the LHR+ and LHR- with respect to the presence of a Golde score \>200 are 30.00 and 0.00, respectively. Hence, if both parameters would turn to be positive, by multiplying the ratios, the post-test detection rate for a PVOD would be around 129∶1. Hence, this study clearly shows that collection of sputum for the analysis of haemosiderin-laden macrophages could be used as an important tool in the diagnostic work-up of PVOD.

Of course, the current case series has its limitations. First, due to the fact that PVOD is a very rare variant of an orphan disease with a prevalence of only 15 patients per one million habitants [@pone.0115219-Humbert1], the number of included patients is low (n = 6). Nevertheless, this has to been put into the context that up to the year 2006, only about 200 cases of PVOD have been reported in the literature. Secondly, a histological confirmation was not obtained from all PVOD patients because lung biopsy is not recommended in these patients [@pone.0115219-Montani2]. Notwithstanding, one patient of the current series underwent lung transplantation, and the Golde score in the tissue was comparable to that found in the sputum. In an other cased, the Golde score from the sputum was comparable to that of the BAL. Thirdly, even due to the fact that sensitivity of the sputum examination for haemosiderin-laden macrophages was statistically 100%, we would like to point out that the diagnostic work-up can further be increased by a proper and repeated sputum collection.

In summary, the present study on patients suffering from PVOD indicates that the collection of non-induced sputum for the analysis of haemosiderin-laden macrophages could be used as a non-invasive diagnostic tool for the work-up of PVOD.
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